Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427683 | 0.80 | RORC (0.46) | GAAKMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL2198579 | 0.79 | KDM4E (0.39) | KDM4E | |
| SCHEMBL13504603 | 0.79 | KDM4E (0.39) | KDM4E | |
| SCHEMBL2195384 | 0.77 | RIPK1 (0.37) | KMT2AKDM4EMEN1 | |
| SCHEMBL2196410 | 0.77 | RIPK1 (0.37) | KMT2AKDM4EMEN1 | |
| SCHEMBL3555287 | 0.76 | CHKA (0.46) | KMT2AMEN1 | |
| SCHEMBL2197629 | 0.75 | KDM4E (0.43) | KMT2AKDM4EALDH1A1MEN1HTT | |
| SCHEMBL2202724 | 0.74 | ALOX5 (0.43) | KMT2AKDM4EMEN1HTT | |
| SCHEMBL352281 | 0.74 | GAA (1.00) | GAAKMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL2196598 | 0.73 | ADRB2 (0.48) | GAAKMT2AKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | GAA 4465/4885KMT2A 904/4885KDM4E 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.